Other hedge funds also recently modified their holdings of the company. Boston Advisors LLC raised its position in Merck & Company by 512.1% in the second quarter. Boston Advisors LLC now owns 374,199 shares of the company’s stock valued at $21,558,000 after buying an additional 313,068 shares during the last quarter. KBC Group NV raised its position in Merck & Company by 32.7% in the third quarter. KBC Group NV now owns 1,398,162 shares of the company’s stock valued at $87,259,000 after buying an additional 344,592 shares during the last quarter. GW&K Investment Management LLC raised its position in Merck & Company by 6.6% in the third quarter. GW&K Investment Management LLC now owns 369,150 shares of the company’s stock valued at $23,039,000 after buying an additional 22,736 shares during the last quarter. Seminole Management Co. Inc. acquired a new position in Merck & Company during the second quarter valued at about $19,783,000. Finally, Badgley Phelps & Bell Inc. raised its position in Merck & Company by 14.4% in the second quarter. Badgley Phelps & Bell Inc. now owns 5,225 shares of the company’s stock valued at $301,000 after buying an additional 657 shares during the last quarter. Institutional investors and hedge funds own 73.80% of the company’s stock.
Mastrapasqua Asset Management Inc. increased its stake in Merck & Company, Inc. (NYSE:MRK) by 1.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 82,798 shares of the company’s stock after buying an additional 965 shares during the period. Mastrapasqua Asset Management Inc.’s holdings in Merck & Company were worth $5,168,000 as of its most recent SEC filing.
Merck & Company, Inc. (NYSE:MRK) traded down 0.37% on Friday, hitting $64.15. 8,531,370 shares of the company were exchanged. The firm’s 50 day moving average is $61.60 and its 200 day moving average is $61.72. The company has a market capitalization of $176.87 billion, a P/E ratio of 31.45 and a beta of 0.79. Merck & Company, Inc. has a 52 week low of $49.24 and a 52 week high of $65.46.
Merck & Company (NYSE:MRK) last posted its quarterly earnings results on Thursday, February 2nd. The company reported $0.89 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.89 by $0.00. The business earned $10.10 billion during the quarter, compared to analysts’ expectations of $10.22 billion. Merck & Company had a net margin of 14.30% and a return on equity of 24.08%. The business’s quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter last year, the company posted $0.93 earnings per share. On average, equities research analysts forecast that Merck & Company, Inc. will post $3.81 earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on MRK shares. Jefferies Group LLC reiterated a “hold” rating and set a $65.00 target price on shares of Merck & Company in a report on Sunday, October 16th. Zacks Investment Research lowered shares of Merck & Company from a “buy” rating to a “hold” rating in a report on Monday, October 17th. Argus reiterated a “buy” rating and set a $80.00 target price (up from $65.00) on shares of Merck & Company in a report on Thursday, October 27th. Finally, Vetr upgraded shares of Merck & Company from a “buy” rating to a “strong-buy” rating and set a $65.80 target price for the company in a report on Tuesday, November 1st. One research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $66.91.
In other news, Director Patricia F. Russo sold 5,000 shares of the stock in a transaction on Wednesday, February 8th. The shares were sold at an average price of $64.42, for a total value of $322,100.00. Following the sale, the director now owns 18,148 shares in the company, valued at $1,169,094.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael J. Holston sold 91,959 shares of the stock in a transaction on Friday, February 3rd. The stock was sold at an average price of $63.96, for a total transaction of $5,881,697.64. Following the completion of the sale, the executive vice president now owns 105,559 shares in the company, valued at approximately $6,751,553.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 106,959 shares of company stock valued at $6,843,448. Corporate insiders own 0.05% of the company’s stock.
About Merck & Company
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).